BPC-157
A synthetic 15-amino-acid peptide studied in tendon tissue and in experiments that track the movement of repair cells.
Explore BPC-157 and TB-500, two experimental peptides investigated for their potential roles in tissue repair, cellular migration and wound-healing processes. Discover their mechanisms of action, preclinical research findings and the differences between these compounds.
BPC-157 and TB-500 are experimental peptides investigated for their potential biological effects on tissue repair and cellular processes.
Although they are frequently discussed together, they are distinct compounds with different origins and research histories.
A synthetic 15-amino-acid peptide studied in tendon tissue and in experiments that track the movement of repair cells.
A synthetic fragment associated with the actin-binding region of thymosin beta-4. The evidence for cell migration depends on which molecule the researchers tested.
BPC-157, also known as Body Protection Compound 157, is a synthetic peptide consisting of 15 amino acids. It has been investigated primarily in studies exploring tissue injury, inflammatory responses, blood vessel formation and gastrointestinal protection. Experimental research has examined its effects on tendon fibroblasts, cellular migration and signaling pathways associated with tissue repair.
TB-500 is the name used in analytical research for a synthetic seven-amino-acid fragment of thymosin beta-4. The full-length molecule has 43 amino acids and helps regulate actin, a protein that supports cell shape and movement. Studies of the fragment and the full-length molecule answer different questions.
Both compounds have attracted research interest because of their potential involvement in biological processes associated with tissue repair. BPC-157 research has explored tendon-related cellular responses and other experimental injury models. Thymosin beta-4 research has investigated cellular migration, actin dynamics and wound-healing pathways.
Researchers examine several parts of the repair process separately. The steps below describe laboratory observations. The combined pen has no established repair mechanism in people.
In rat tendon cells, Chang and colleagues recorded changes in two proteins, FAK and paxillin, that help cells attach to their surroundings and move.
Fibroblasts moved out of rat Achilles tendon tissue in a BPC-157 experiment. In a separate study, skin cells migrated in response to full-length thymosin beta-4.
Angiogenesis is the growth of new vessels from existing ones. Researchers studying BPC-157 measured changes in the VEGFR2 signaling pathway in blood vessel cells and in blood flow through injured rat limbs.
Tendon, muscle and skin models let researchers measure one part of repair at a time. Cells moving in a dish cannot show whether an injured person regains strength or returns to activity.
The strongest distinction in this literature is between an experiment that tracks cells and one that follows a patient. It also matters whether the researchers studied BPC-157, the TB-500 fragment or full-length thymosin beta-4.
Rat tendon samples exposed to BPC-157 produced more fibroblast outgrowth by day seven. Cells also migrated more readily in culture. These endpoints describe cell behavior. The investigators did not measure ligament strength or recovery time in people.
An analysis of horse urine and plasma identified the synthetic fragment used in a specific TB-500 preparation. A separate rat wound study found more skin regrowth with full-length thymosin beta-4 at days four and seven. Only the second study tested a wound outcome, and it used the longer molecule.
A 2026 experiment assigned 32 rats with surgically repaired Achilles tendons to four groups. Four weeks later, the combination showed no additional benefit over the individual agents. The investigators called their second peptide synthetic thymosin beta-4 (TB-500) and did not publish its sequence. The paper therefore cannot confirm a result for the seven-amino-acid fragment or this particular pen.
A retrospective knee-pain report reached 16 people. Twelve had received BPC-157 alone and four had also received a substance the authors named thymosin beta-4. They reported pain by telephone, with no control group or imaging to demonstrate tissue repair. The report cannot establish synergy or show that the pen sold here repairs an injury.
The names describe different molecules. Checking the exact peptide in a paper helps explain which findings can be applied to the question at hand.
| Molecule | Identity | What the cited research measured |
|---|---|---|
| BPC-157 | Synthetic peptide with 15 amino acids | Outgrowth and movement of tendon cells, blood vessel signaling and blood flow in animal models. |
| TB-500 | In the cited analytical paper, an acetylated seven-amino-acid fragment from thymosin beta-4 | Identification of the fragment and its metabolites in horse samples. This study did not test healing. |
| Full-length thymosin beta-4 (Tβ4) | Naturally occurring peptide with 43 amino acids that interacts with actin | Migration of skin cells in culture and wound closure in rats treated with the full-length molecule. |
The Body Pharm catalog lists BPC-157 and TB-500 together. The names and stated quantities alone cannot verify the fragment identity in a particular lot or establish a clinical effect of the combination.
Find both BPC157 and TB500 on the silver pen or carton. A box that shows only one ingredient is a different product.
| Specification | Details |
|---|---|
| Product | BPC-157 + TB-500 |
| Brand | Body Pharm |
| Format | Prefilled pen |
| Labelled blend | 16 mg BPC-157 + 16 mg TB-500 |
| Total per pen | 32 mg |
| Price per pen | IDR 3,000,000 |
| Storage on the label | 2–8°C, protected from light |
You can read the manufacturer’s report here. To check your own carton, ask for the document with the same batch number as the box.
The label gives a storage range of 2–8°C. Keep the carton away from light and the freezer. If it arrives warm or damaged, keep the packaging and contact the team before using it.
See the amount and price for each complete pen.
BPC-157 is a synthetic peptide consisting of 15 amino acids. It has been investigated primarily in laboratory and animal studies exploring tissue injury, cellular migration, inflammation and gastrointestinal protection.
TB-500 is a synthetic peptide associated with thymosin beta-4-related research. Thymosin beta-4 is involved in biological processes including actin regulation and cellular migration. TB-500 should not automatically be considered identical to full-length thymosin beta-4.
Experimental studies suggest that BPC-157 may influence cellular signaling pathways involved in tissue responses and repair. Its precise mechanisms and clinical effects in humans have not been adequately established.
Research involving thymosin beta-4-related pathways has examined actin regulation, cellular migration and wound-healing mechanisms. However, findings involving full-length thymosin beta-4 cannot automatically be applied to TB-500.
BPC-157 is a synthetic 15-amino-acid peptide investigated in experimental tissue injury models. TB-500 is associated with thymosin beta-4-related research. Their molecular structures, proposed mechanisms and available evidence differ.
A four-week rat experiment tested substances the authors called BPC-157 and TB-500 together and found no additional benefit. There is insufficient high-quality human clinical evidence evaluating the combination. Claims of enhanced or synergistic recovery effects have not been established.
Research involving thymosin beta-4-related pathways has explored biological processes relevant to tissue repair. There is insufficient direct clinical evidence to establish that TB-500 improves muscle recovery in humans.
There is insufficient human clinical evidence demonstrating that either compound repairs damaged ligaments or accelerates recovery from ligament injuries.
Most published BPC-157 research involves laboratory experiments and animal models. Findings have explored tissue injury, cellular migration and other biological processes, but reliable human efficacy data remain extremely limited.
Reliable human safety data are insufficient to establish a comprehensive adverse-effect profile. Potential risks, interactions and long-term effects remain inadequately characterized.
Body Pharm lists 16 mg of BPC-157 and 16 mg of TB-500, for a combined stated content of 32 mg in the whole pen.
A combination formulation contains two named components in one product. Separate formulations contain the compounds individually. The presence of both ingredients does not establish that their effects are additive or synergistic.
Storage conditions depend on the formulation. The Body Pharm pen is described with refrigerated storage conditions of 2–8°C, which should be verified against the manufacturer’s documentation.
Published research can be found in peer-reviewed scientific journals and biomedical databases. When reviewing studies, it is important to distinguish laboratory experiments, animal studies and human clinical trials.
Read the original tendon, peptide-identification and wound studies. Each entry identifies the molecule and experimental model.
BPC-157 increased cell outgrowth from tendon samples and migration in culture, and improved cell survival under oxidative stress.
Read Original StudyThe combination provided no additional benefit over the individual treatments on the tendon measures assessed.
Read Original StudyThe authors detected an acetylated seven-amino-acid fragment of thymosin beta-4 and its breakdown products in equine samples.
Read Original StudyFull-length thymosin beta-4 increased regrowth of the skin surface in rats compared with saline, while the separate cell assay showed increased migration.
Read Original StudyTell us how many BPC-157 + TB-500 pens you want and where in Bali you are staying. We can confirm availability, the delivered price and a time that works for you.